Navigation Links
Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
Date:6/14/2013

PITTSBURGH, June 14, 2013 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG) today announced a reduction in staff and levels of investment that were necessitated by delays in portfolio company exits caused primarily by the current overall investment climate and the uncertainty of state funding.

PLSG President and CEO, John W. Manzetti said, "As the region's only pure life sciences investment firm, the actions taken this week, which were approved by the PLSG Board of Directors, were necessary to protect the future of both our base economic development activities and our investments in both the PLSG and PLSG Accelerator Fund companies.

"These actions will remove expenses related to community and company support and services but still enable us to focus on investments. As our strong portfolio of companies achieve their awaited exits, the PLSG will return to historic levels of annual investment. We have centered our focus on the PLSG's premier Executive Program and have protected our ability to invest modestly until these returns are realized.  Our experienced and highly-focused investment team remains passionate and committed to the growth of the region's important life sciences sector."

About Pittsburgh Life Sciences Greenhouse (PLSG) (www.plsg.com)
The PLSG invests in and supports the growth of biosciences companies in western Pennsylvania. PLSG has a track record of excellence when it comes to attracting and growing life sciences companies in the region. Since its inception in 2001, PLSG has assisted more than 400 life sciences companies and has helped create or retain nearly 6,000 jobs in western Pennsylvania. Thirty-four companies have been provided with office or laboratory space and 13 have been relocated to Pittsburgh from outside of the region. In addition, the PLSG has invested $18.9 million in 76 companies which has leveraged nearly $900 million in additional capital to the region.

About PLSG Accelerator Fund (www.acceleratorfund.com )
The PLSG Accelerator Fund I, which had its final closing in December, 2012 at $8.1 million, currently is fully invested in eight portfolio companies.  The Accelerator Fund provides regional life sciences companies with venture capital financing, which is the next step beyond capital provided by economic development organizations; friends and family; and angel investors.  The Accelerator Fund is building a portfolio of early-stage life sciences investments, primarily located in western Pennsylvania and spread across several life sciences investments, primarily located in western Pennsylvania and spread across several life sciences sectors including medical devices, diagnostics, therapeutics, healthcare information technology and biotechnology tools.  The value proposition of the Fund is at least two-fold: (1) PLSG executive manage the Fund, affording investors with quality of personnel that likely would be otherwise available only through significantly larger funds; (2) only companies that have already performed successfully using PLSG investments and programs are considered for Fund investment.


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
2. The Pittsburgh Life Sciences Greenhouse Congratulates Dr. Paul L. Kornblith, M.D., on Being Named the 2013 recipient of the Schoemaker Award
3. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
4. Pittsburghs Positive Investment Growth Bucks National Trends According to Ernst & Young and Innovation Works Report
5. Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device
6. Garage Start-ups Now Possible in Life Sciences Industry
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. DiaTech Life Sciences Announces Medical Advisory Board
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):